Chicago—As more state legislatures are relaxing anti-marijuana laws, physicians are being put in the middle by patients requesting prescriptions or authorizations for its use for medical needs, said Marc F. Lieberman, MD.
Discussing the topic of medicinal cannabis for glaucoma, Dr. Leiberman explained that the consistent conclusion—based on years of study—is that marijuana is less effective than currently available topical glaucoma therapies and is inappropriate for glaucoma management.
“At the end of 2014, there is broad consensus from the FDA, the National Eye Institute, and ophthalmological societies . . . that there is no current role for use of cannabis agents in the management of glaucoma,” said Dr. Lieberman, clinical professor of ophthalmology, University of California San Francisco. “I encourage all of us as ophthalmologists to proclaim clearly there is no therapeutically useful reason for marijuana to be used as management for chronic IOP reduction.
“In my personal practice, I educate my patients, I refrain from prescribing marijuana, and I try to do no harm,” he continued.